How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas

References

• ChaplinDDOverview of the immune responseJ Allergy Clin Immunol20101252 Suppl 2S3S2320176265
   PubMed Web of Science ®Google Scholar
• LipmanNSJacksonLRTrudelLJWeis-GarciaFMonoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resourcesILAR J200546325826815953833
   PubMed Web of Science ®Google Scholar
• ParhamPAntibody Structure and the Generation of B-Cell DiversityParhamPThe Immune System3rd edNew YorkGarland Science, Taylor & Francis Group200995121
   Google Scholar
• RuiLGoodnowCCLymphoma and the control of B cell growth and differentiationCurr Mol Med20066329130816712476
   PubMed Web of Science ®Google Scholar
• ManiHJaffeESHodgkin lymphoma: an update on its biology with new insights into classificationClin Lymphoma Myeloma20099320621619525189
   PubMedGoogle Scholar
• The Leukemia & Lymphoma SocietyThe lymphoma guideLeuk Lymphoma Soc2013148
   Google Scholar
• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20141365E359E38625220842
   PubMed Web of Science ®Google Scholar
• Non-Hodgkin lymphoma statistics | Cancer Research UK Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-hodgkin-lymphomaAccessed August 24, 2018
   Google Scholar
• GallagherCJListerTASMMalignant diseaseKumarPClarkMKumar and Clark’s Clinical MedicineEighth Edi EdinburghSaunders/Elsevier2012461469
   Google Scholar
• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health organization classification of lymphoid neoplasmsBlood2016127202375239026980727
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th edWorld Health Organsiation2008
   Google Scholar
• FrampasELymphomas: basic points that radiologists should knowDiagn Interv Imaging201394213114423273947
   PubMedGoogle Scholar
• HarrisonAMThaljiNMGreenbergAJTapiaCJWindebankAJRituximab for non-Hodgkin’s lymphoma: a story of rapid success in translationClin Transl Sci201471828624528902
   PubMed Web of Science ®Google Scholar
• ArmitageJOGascoyneRDLunningMACavalliFNon-Hodgkin lymphomaLancet20173901009129831028153383
   PubMed Web of Science ®Google Scholar
• MeyUHitzFLohriADiagnosis and treatment of diffuse large B-cell lymphomaSwiss Med Wkly20121421115
   Google Scholar
• Survival | non-Hodgkin lymphoma | Cancer Research UK Available from: https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/survivalAccessed September 3, 2018
   Google Scholar
• DotanEAggarwalCSmithMRImpact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphomaP T201035314815720442809
   PubMedGoogle Scholar
• FisherRIGaynorERDahlbergSComparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphomaN Engl J Med199332814100210067680764
   PubMed Web of Science ®Google Scholar
• SonneveldPDe RidderMVan der LelieHComparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapyJ Clin Oncol19951310253025397595704
   PubMed Web of Science ®Google Scholar
• DixonDONeilanBJonesSEEffect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the southwest Oncology Group experienceJ Clin Oncol1986432953053512783
   PubMed Web of Science ®Google Scholar
• ZinzaniPLStortiSZaccariaAElderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patientsBlood1999941333810381495
   PubMed Web of Science ®Google Scholar
• CoiffierBWhat treatment for elderly patients with aggressive lymphoma?Ann Oncol19945108738757696157
   PubMed Web of Science ®Google Scholar
• MaloneyDGLilesTMCzerwinskiDKPhase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood1994848245724667522629
   PubMed Web of Science ®Google Scholar
• CartwrightRBrinckerHCarliPMThe rise in incidence of lymphomas in Europe 1985–1992Eur J Cancer199935462763310492638
   PubMed Web of Science ®Google Scholar
• KöhlerGMilsteinCContinuous cultures of fused cells secreting antibody of predefined specificityNature197525655174954971172191
   PubMed Web of Science ®Google Scholar
• NadlerLMStashenkoPHardyRSerotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigenCancer Res1980409314731547427932
   PubMed Web of Science ®Google Scholar
• MillerRAMaloneyDGWarnkeRLevyRTreatment of B-cell lymphoma with monoclonal anti-idiotype antibodyN Engl J Med198230695175226173751
   PubMed Web of Science ®Google Scholar
• PressOWAppelbaumFLedbetterJAMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomasBlood19876925845913492224
   PubMed Web of Science ®Google Scholar
• ReffMECarnerKChambersKSDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood19948324354457506951
   PubMed Web of Science ®Google Scholar
• FDARituximab - Product Approval Information - Licensing Action Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1997/ritugen112697L.htm. Published 1997Accessed August 24, 2018
   Google Scholar
• Two New Indications Approved for Rituximab in NHL | Cancer NetworkThe Cancer Network Available from: http://www.cancernetwork.com/hematologic-malignancies/two-new-indications-approved-rituximab-nhl. Published 2006Accessed August 27, 2018
   Google Scholar
• MouldDRMeibohmBDrug development of therapeutic monoclonal antibodiesBioDrugs201630427529327342605
   PubMed Web of Science ®Google Scholar
• The Lymphoma Research FoundationNon-Hodgkin lymphomaThe lymphoma Research Foundation Available from: https://www.lymphoma.org/aboutlymphoma/nhl/Accessed August 27, 2018
   Google Scholar
• StashenkoPNadlerLMHardyRSchlossmanSFCharacterization of a human B lymphocyte-specific antigenJ Immunol19801254167816856157744
   PubMed Web of Science ®Google Scholar
• ClarkEAShuGLedbetterJARole of the Bp35 cell surface polypeptide in human B-cell activationProc Natl Acad Sci USA1985826176617703872456
   PubMed Web of Science ®Google Scholar
• OettgenHCBayardPJvan EwijkWNadlerLMTerhorstCPFurther biochemical studies of the human B-cell differentiation antigens B1 and B2Hybridoma19832117286432678
   PubMedGoogle Scholar
• EinfeldDABrownJPValentineMAClarkEALedbetterJAMolecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domainsEMBO J1988737117172456210
   PubMed Web of Science ®Google Scholar
• StamenkovicISeedBAnalysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane proteinJ Exp Med19881676197519803260267
   PubMed Web of Science ®Google Scholar
• TedderTFBoydAWFreedmanASNadlerLMSchlossmanSFThe B cell surface molecule B1 is functionally linked with B cell activation and differentiationJ Immunol198513529739793925015
   PubMed Web of Science ®Google Scholar
• ValentineMAMeierKERossieSClarkEAPhosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase CJ Biol Chem19892641911282112872472394
   PubMed Web of Science ®Google Scholar
• O’KeefeTLWilliamsGTDaviesSLNeubergerMSMice carrying a CD20 gene disruptionImmunogenetics19984821251329634476
   PubMed Web of Science ®Google Scholar
• UchidaJLeeYHasegawaMMouse CD20 expression and functionInt Immunol200416111912914688067
   PubMed Web of Science ®Google Scholar
• TedderTFForsgrenABoydAWNadlerLMSchlossmanSFAntibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytesEur J Immunol19861688818873091375
   PubMed Web of Science ®Google Scholar
• BubienJKZhouLJBellPDFrizzellRATedderTFTransfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytesJ Cell Biol19931215112111327684739
   PubMed Web of Science ®Google Scholar
• TedderTFEngelPCD20: a regulator of cell-cycle progression of B lymphocytesImmunol Today19941594504547524522
   PubMedGoogle Scholar
• PolyakMJDeansJPAlanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structureBlood20029993256326211964291
   PubMed Web of Science ®Google Scholar
• DemidemALamTAlasSHariharanKHannaNBonavidaBChimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugsCancer Biother Radiopharm199712317718610851464
   PubMed Web of Science ®Google Scholar
• FliegerDRenothSBeierISauerbruchTSchmidt-WolfIMechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell linesCell Immunol20002041556311006018
   PubMed Web of Science ®Google Scholar
• ChomczynskiPSacchiNSingle-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extractionAnal Biochem198716211561592440339
   PubMed Web of Science ®Google Scholar
• RobinsonRRChartierJChangCPHorwitzAHBetterMChimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activitiesHuman Antibodies1991228493
   Google Scholar
• MaloneyDGGrillo-LópezAJBodkinDJIDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol19971510326632749336364
   PubMed Web of Science ®Google Scholar
• MclaughlinPGrillo-LópezAJLinkBKRituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programJ Clin Oncol1998168282528339704735
   PubMed Web of Science ®Google Scholar
• FDAGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products Guidance for Industry FDA Approval of New Cancer1998 Available from: http://www.fda.gov/cber/guidelines.htmAccessed August 24, 2018
   Google Scholar
• Van NormanGADrugs, devices, and the FDA: Part 1: an overview of approval processes for drugsJACC Basic to Transl Sci201613170179
   PubMedGoogle Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors ProjectA predictive model for aggressive non-Hodgkin’s lymphomaN Engl J Med1993329149879948141877
   PubMed Web of Science ®Google Scholar
• CoiffierBLepageEBrièreJCHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphomaN Engl J Med2002346423524211807147
   PubMed Web of Science ®Google Scholar
• DudleyWNWickhamRCoombsNAn introduction to survival statistics: Kaplan-Meier analysisJ Adv Pract Oncol2016719110027713848
   PubMedGoogle Scholar
• PfreundschuhMTrümperLÖsterborgACHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (mint) groupLancet Oncol20067537939116648042
   PubMed Web of Science ®Google Scholar
• HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935
   PubMed Web of Science ®Google Scholar
• SehnLHDonaldsonJChhanabhaiMIntroduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British ColumbiaJ Clin Oncol200523225027503315955905
   PubMed Web of Science ®Google Scholar
• HasselblomSStensonMWerleniusOImproved outcome for very elderly patients with Diff use large B-cell lymphoma in the immunochemotherapy eraLeuk Lymphoma201253339439921864039
   PubMed Web of Science ®Google Scholar
• KrauseSWGerkenMAndreesenRHofstädterFKlinkhammer-SchalkeMTreatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registryAnn Hematol201291456157022200972
   PubMed Web of Science ®Google Scholar
• LeeLCrumpMKhorSImpact of rituximab on treatment outcomes of patients with diffuse large B-cell lymphoma: a population-based analysisBr J Haematol2012158448148822671571
   PubMed Web of Science ®Google Scholar
• MianMAugustinFKocherFA success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphomaAnticancer Res20143452559256424778077
   PubMed Web of Science ®Google Scholar
• VidalLGafter-GviliASallesGRituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysisEur J Cancer20177621622528336303
   PubMed Web of Science ®Google Scholar
• VoseJMMantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical managementAm J Hematol201590873974526103436
   PubMed Web of Science ®Google Scholar
• FanFWangWGuanglunLEfficacy and safety of rituximab in marginal zone lymphoma: a meta-analysis of 13 studiesInt J Clin Exp Med2015810175151752226770342
   PubMed Web of Science ®Google Scholar
• NICE GuidelinesNon-Hodgkin’s lymphoma: rituximab subcutaneous injection2014 Available from: https://www.nice.org.uk/advice/esnm46/chapter/full-evidence-summaryAccessed August 26, 2018
   Google Scholar
• DaviesABergeCBoehnkeASubcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical developmentAdv Ther201734102210223128983819
   PubMed Web of Science ®Google Scholar
• DaviesAMerliFMihaljevicBPharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 studyLancet Oncol201415334335224521993
   PubMed Web of Science ®Google Scholar
• GreenDJPressOWWhither radioimmunotherapy: to be or not to be?Cancer Res20177792191219628428282
   PubMed Web of Science ®Google Scholar
• YinHMengTShuLNovel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin’s lymphomaChem Biol Drug Des201790589289928440948
   PubMed Web of Science ®Google Scholar
• CangSMukhiNWangKLiuDNovel CD20 monoclonal antibodies for lymphoma therapyJ Hematol Oncol2012516423057966
   PubMed Web of Science ®Google Scholar
• AlizadehAAEisenMBDavisREDistinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature2000403676950351110676951
   PubMed Web of Science ®Google Scholar
• LeonardJPKolibabaKSReevesJARandomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphomaJ Clin Oncol201735313538354628862883
   PubMed Web of Science ®Google Scholar